101 related articles for article (PubMed ID: 33742764)
1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.
Grippo JF; Folitar I; Passe S; Jiang Q; Rodriguez I; Fettner SH; Calleja E
Clin Transl Sci; 2021 Jul; 14(4):1524-1534. PubMed ID: 33742764
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
Port A; Shaw JV; Klopp-Schulze L; Bytyqi A; Vetter C; Hussey E; Mammasse N; Ona V; Bachmann A; Strugala D; Reh C; Goteti K
Pharmacol Res Perspect; 2021 Oct; 9(5):e00842. PubMed ID: 34414672
[TBL] [Abstract][Full Text] [Related]
3. Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-Ascending Doses of Sunobinop in Healthy Participants.
Cipriano A; Kapil RP; Zhou M; Shet MS; Whiteside GT; Willsie SK; Harris SC
Clin Pharmacol Drug Dev; 2024 Jul; 13(7):790-800. PubMed ID: 38476082
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Jani RH; Kansagra K; Jain MR; Patel H
Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
[TBL] [Abstract][Full Text] [Related]
5. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
Schmitt-Hoffmann A; Roos B; Heep M; Schleimer M; Weidekamm E; Brown T; Roehrle M; Beglinger C
Antimicrob Agents Chemother; 2006 Jan; 50(1):279-85. PubMed ID: 16377698
[TBL] [Abstract][Full Text] [Related]
6. Safety, Pharmacokinetics, and Pharmacodynamics of Etrasimod: Single and Multiple Ascending Dose Studies in Healthy Adults.
Lee CA; Schreiber S; Bressler B; Adams JW; Oh DA; Tang YQ; Zhang J; Komori HK; Grundy JS
Clin Pharmacol Drug Dev; 2024 May; 13(5):534-548. PubMed ID: 38345530
[TBL] [Abstract][Full Text] [Related]
7. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants.
Hincelin-Mery A; Nicolas X; Cantalloube C; Pomponio R; Lewanczyk P; Benamor M; Ofengeim D; Krupka E; Hsiao-Nakamoto J; Eastenson A; Atassi N
Clin Transl Sci; 2024 Jan; 17(1):e13690. PubMed ID: 38010108
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women.
Clark RV; Walker AC; Andrews S; Turnbull P; Wald JA; Magee MH
Br J Clin Pharmacol; 2017 Oct; 83(10):2179-2194. PubMed ID: 28449232
[TBL] [Abstract][Full Text] [Related]
10. Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study.
Xu J; Zhang H; Chen H; Zhu X; Jia H; Xu Z; Huo D; Zhang H; Li C; Ding Y
Ann Med; 2023; 55(2):2264850. PubMed ID: 38071661
[No Abstract] [Full Text] [Related]
11. Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.
Vandell AG; Inoue S; Dennie J; Nagasawa Y; Gajee R; Pav J; Zhang G; Zamora C; Masuda N; Senaldi G
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439973
[TBL] [Abstract][Full Text] [Related]
12. Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
Datta-Mannan A; Regev A; Coutant DE; Dropsey AJ; Foster J; Jones S; Poorbaugh J; Schmitz C; Wang E; Woodman ME
Clin Pharmacol Ther; 2024 May; 115(5):1152-1161. PubMed ID: 38294091
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-β agonist for treatment of spinal cord injury, in male healthy participants.
Goncalves MB; Mant T; Täubel J; Clarke E; Hassanin H; Bendel D; Fok H; Posner J; Holmes J; Mander AP; Corcoran JPT
Br J Clin Pharmacol; 2023 Dec; 89(12):3573-3583. PubMed ID: 37452623
[TBL] [Abstract][Full Text] [Related]
14. A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.
Jones NS; Kshirsagar S; Mohanan V; Ramakrishnan V; Di Nucci F; Ma L; Mao J; Ding H; Klabunde S; Vucic D; Pan L; Lekkerkerker AN; Chen Y; Rothenberg ME
Clin Transl Sci; 2023 Oct; 16(10):1997-2009. PubMed ID: 37596814
[TBL] [Abstract][Full Text] [Related]
15. First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration.
Bazydło-Guzenda K; Jarus-Dziedzic K; Gierczak-Pachulska A; Buda P; Rudzki PJ; Buś-Kwaśnik K; Juszczyk E; Tratkiewicz E; Rabczenko D; Segiet-Święcicka A; Wieczorek M
Diabetes Obes Metab; 2024 Apr; 26(4):1376-1385. PubMed ID: 38204407
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study.
Modi NB; Shames R; Lickliter JD; Gupta S
Eur J Haematol; 2024 May; ():. PubMed ID: 38785334
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi-ascending dose study with a bioequivalence arm in healthy volunteers.
Kirkpatrick DL; Evans C; Pestano LA; Millard J; Johnston M; Mick E; Schmidt WK
Clin Transl Sci; 2024 Mar; 17(3):e13765. PubMed ID: 38511523
[TBL] [Abstract][Full Text] [Related]
18. First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus.
Zhou X-J; Lickliter J; Montrond M; Ishak L; Pietropaolo K; James D; Belanger B; Horga A; Hammond J
Antimicrob Agents Chemother; 2024 May; 68(5):e0161523. PubMed ID: 38526047
[TBL] [Abstract][Full Text] [Related]
19. Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
Zhou S; Xie L; Zhou C; Wang L; Chen J; Ding S; Zhu B; Su M; Shao F
Clin Transl Sci; 2023 Oct; 16(10):1911-1922. PubMed ID: 37533172
[TBL] [Abstract][Full Text] [Related]
20. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
